10 research outputs found
Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen
AbstractThe establishment of protocols to differentiate human pluripotent stem cells (hPSCs) including embryonic (ESC) and induced pluripotent (iPSC) stem cells into functional hepatocyte-like cells (HLCs) creates new opportunities to study liver metabolism, genetic diseases and infection of hepatotropic viruses (hepatitis B and C viruses) in the context of specific genetic background. While supporting efficient differentiation to HLCs, the published protocols are limited in terms of differentiation into fully mature hepatocytes and in a smaller-well format. This limitation handicaps the application of these cells to high-throughput assays. Here we describe a protocol allowing efficient and consistent hepatic differentiation of hPSCs in 384-well plates into functional hepatocyte-like cells, which remain differentiated for more than 3weeks. This protocol affords the unique opportunity to miniaturize the hPSC-based differentiation technology and facilitates screening for molecules in modulating liver differentiation, metabolism, genetic network, and response to infection or other external stimuli
Molecular Mechanisms of the Hepatitis E Virus Life Cycle and Host Range
At least 20 million hepatitis E virus (HEV) infections occur annually, with >3 million symptomatic cases and ~60,000 fatalities. Hepatitis E is generally self-limiting with a case fatality rate of 0.5-3% in young adults. However, it can cause up to 30% mortality in pregnant women in the third trimester, and can become chronic in immunocompromised individuals such as those receiving organ transplants or chemotherapy and individuals with HIV infection. HEV is transmitted primarily via the fecal–oral route, and was previously thought to be a public health concern only in developing countries. It is now also being frequently reported in industrialized countries, where it is transmitted zoonotically, or through organ transplantation or blood transfusions. Although a vaccine for HEV has been developed, it is only licensed in China. Additionally, no effective, non-teratogenic and specific treatments against HEV infections are currently available. Although progress has been made in characterizing HEV biology, the scarcity of adequate experimental platforms has hampered further research. The work presented in this dissertation advances our knowledge on HEV in three key areas: (i) the development of screening tools for and the identification of novel therapeutic compounds against HEV (Chapter 2); (ii) understanding the range of hosts susceptible to HEV infection (Chapter 3), and (iii) elucidating the mechanisms through which the virus replicates its genome and exits from the host cell (Chapters 4-5)
Hepatitis E Virus Replication
Hepatitis E virus (HEV) is a small quasi-enveloped, (+)-sense, single-stranded RNA virus belonging to the Hepeviridae family. There are at least 20 million HEV infections annually and 60,000 HEV-related deaths worldwide. HEV can cause up to 30% mortality in pregnant women and progress to liver cirrhosis in immunocompromised individuals and is, therefore, a greatly underestimated public health concern. Although a prophylactic vaccine for HEV has been developed, it is only licensed in China, and there is currently no effective, non-teratogenic treatment. HEV encodes three open reading frames (ORFs). ORF1 is the largest viral gene product, encoding the replicative machinery of the virus including a methyltransferase, RNA helicase, and an RNA-dependent RNA polymerase. ORF1 additionally contains a number of poorly understood domains including a hypervariable region, a putative protease, and the so-called ‘X’ and ‘Y’ domains. ORF2 is the viral capsid essential for formation of infectious particles and ORF3 is a small protein essential for viral release. In this review, we focus on the domains encoded by ORF1, which collectively mediate the virus’ asymmetric genome replication strategy. We summarize what is known, unknown, and hotly debated regarding the coding and non-coding regions of HEV ORF1, and present a model of how HEV replicates its genome
Recommended from our members
Hepatitis E Virus Replication.
Hepatitis E virus (HEV) is a small quasi-enveloped, (+)-sense, single-stranded RNA virus
belonging to the Hepeviridae family. There are at least 20 million HEV infections annually and 60,000
HEV-related deaths worldwide. HEV can cause up to 30% mortality in pregnant women and progress
to liver cirrhosis in immunocompromised individuals and is, therefore, a greatly underestimated
public health concern. Although a prophylactic vaccine for HEV has been developed, it is only licensed
in China, and there is currently no effective, non-teratogenic treatment. HEV encodes three open
reading frames (ORFs). ORF1 is the largest viral gene product, encoding the replicative machinery of
the virus including a methyltransferase, RNA helicase, and an RNA-dependent RNA polymerase.
ORF1 additionally contains a number of poorly understood domains including a hypervariable region,
a putative protease, and the so-called ‘X’ and ‘Y’ domains. ORF2 is the viral capsid essential for
formation of infectious particles and ORF3 is a small protein essential for viral release. In this review,
we focus on the domains encoded by ORF1, which collectively mediate the virus’ asymmetric genome
replication strategy. We summarize what is known, unknown, and hotly debated regarding the
coding and non-coding regions of HEV ORF1, and present a model of how HEV replicates its genome
Recommended from our members
Identification of the Intragenomic Promoter Controlling Hepatitis E Virus Subgenomic RNA Transcription
Approximately 20 million hepatitis E virus (HEV) infections occur annually in both developing and industrialized countries. Most infections are self-limiting, but they can lead to chronic infections and cirrhosis in immunocompromised patients, and death in pregnant women. The mechanisms of HEV replication remain incompletely understood due to scarcity of adequate experimental platforms. HEV undergoes asymmetric genome replication, but it produces an additional subgenomic (SG) RNA encoding the viral capsid and a viroporin in partially overlapping open reading frames. Using a novel transcomplementation system, we mapped the intragenomic subgenomic promoter regulating SG RNA synthesis. This cis-acting element is highly conserved across all eight HEV genotypes, and when the element is mutated, it abrogates particle assembly and release. Our work defines previously unappreciated viral regulatory elements and provides the first in-depth view of the intracellular genome dynamics of this emerging human pathogen.HEV is an emerging pathogen causing severe liver disease. The genetic information of HEV is encoded in RNA. The genomic RNA is initially copied into a complementary, antigenomic RNA that is a template for synthesis of more genomic RNA and for so-called subgenomic RNA. In this study, we identified the precise region within the HEV genome at which the synthesis of the subgenomic RNA is initiated. The nucleotides within this region are conserved across genetically distinct variants of HEV, highlighting the general importance of this segment for the virus. To identify this regulatory element, we developed a new experimental system that is a powerful tool with broad utility to mechanistically dissect many other poorly understood functional elements of HEV
Recommended from our members
Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles
Hepatitis E virus (HEV) is the leading cause of enterically transmitted
viral hepatitis globally. Of HEV’s three ORFs, the function of ORF3 has
remained elusive. Here, we demonstrate that via homophilic interactions ORF3 forms multimeric complexes associated with intracellular
endoplasmic reticulum (ER)-derived membranes. HEV ORF3 shares several structural features with class I viroporins, and the function of HEV
ORF3 can be maintained by replacing it with the well-characterized
viroporin influenza A virus (IAV) matrix-2 protein. ORF3’s ion channel
function is further evidenced by its ability to mediate ionic currents
when expressed in Xenopus laevis oocytes. Furthermore, we identified several positions in ORF3 critical for its formation of multimeric
complexes, ion channel activity, and, ultimately, release of infectious
particles. Collectively, our data demonstrate a previously undescribed
function of HEV ORF3 as a viroporin, which may serve as an attractive
target in developing direct-acting antiviral
Recommended from our members
Hepatitis E virus ORF3 is a functional ion channel required for release of infectious particles
Hepatitis E virus (HEV) is the leading cause of enterically transmitted viral hepatitis globally. Of HEV’s three ORFs, the function of ORF3 has remained elusive. Here, we demonstrate that via homophilic interactions ORF3 forms multimeric complexes associated with intracellular endoplasmic reticulum (ER)-derived membranes. HEV ORF3 shares several structural features with class I viroporins, and the function of HEV ORF3 can be maintained by replacing it with the well-characterized viroporin influenza A virus (IAV) matrix-2 protein. ORF3’s ion channel function is further evidenced by its ability to mediate ionic currents when expressed in Xenopus laevis oocytes. Furthermore, we identified several positions in ORF3 critical for its formation of multimeric complexes, ion channel activity, and, ultimately, release of infectious particles. Collectively, our data demonstrate a previously undescribed function of HEV ORF3 as a viroporin, which may serve as an attractive target in developing direct-acting antivirals
Engrafted human stem cell–derived hepatocytes establish an infectious HCV murine model
Recommended from our members
Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90
Hepatitis E virus (HEV) causes 14 million infections and 60,000 deaths per year globally, with
immunocompromised persons and pregnant women experiencing severe symptoms. Although
ribavirin can be used to treat chronic hepatitis E, toxicity in pregnant patients and the emergence
of resistant strains are major concerns. Therefore there is an imminent need for effective HEV
antiviral agents. The aims of this study were to develop a drug screening platform and to discover
novel approaches to targeting steps within the viral life cycle. We developed a screening platform
for molecules inhibiting HEV replication and selected a candidate, isocotoin. Isocotoin inhibits
HEV replication through interference with heat shock protein 90 (HSP90), a host factor not
previously known to be involved in HEV replication. Additional work is required to understand the compound’s translational potential, however this suggests that HSP90-modulating molecules,
which are in clinical development as anti-cancer agents, may be promising therapies against HEV